XNAS
EMBC
Market cap341mUSD
Oct 08, Last price
5.75USD
1D
-2.71%
1Q
77.47%
IPO
-81.15%
Name
Embecta Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
Key people
Chairman of the Board, President, Chief Executive Officer · since 2025
Jean Casner
Chief Human Resources Officer, Senior Vice President · since 2023
Ginny Blocki
Senior Vice President - Strategy · since 2024
Tom Blount
Senior Vice President and President, North America · since 2022
Shaun Curtis
Senior Vice President - Global Manufacturing, Supply Chain and Quality · since 2024
Jacob Elguicze
Chief Financial Officer, Senior Vice President · since 2022
Anthony Roth
Vice President, Chief Accounting Officer, Corporate Controller · since 2024
Slobodan Radumilo
Senior Vice President and President - International · since 2022
Jeffrey Mann
Senior Vice President, General Counsel, Product Development · since 2024
Lead Independent Director · since 2025
Independent Director · since 2022
Independent Director · since 2022
Milton Morris
Independent Director · since 2022
Independent Director · since 2022
Independent Director · since 2022
Legal address
C/O THE CORPORATION TRUST COMPANY
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
1209 ORANGE ST
WILMINGTON, DE 19801
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||